Base de dados : LILACS
Pesquisa : D03.383.129.308 [Categoria DeCS]
Referências encontradas : 203 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 21 ir para página                         

  1 / 203 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Costa, Carlos Alberto de Souza
Texto completo
Id: biblio-951982
Autor: Basso, Fernanda Gonçalves; Soares, Diana Gabriela; Pansani, Taisa Nogueira; Turrioni, Ana Paula Silveira; Scheffel, Débora Lopes; Hebling, Josimeri; Costa, Carlos Alberto de Souza.
Título: Response of a co-culture model of epithelial cells and gingival fibroblasts to zoledronic acid
Fonte: Braz. oral res. (Online);30(1):e122, 2016. graf.
Idioma: en.
Projeto: São Paulo Research Foundation; . São Paulo Research Foundation; . Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Resumo: Abstract Osteonecrosis of the jaw is an adverse effect of bisphosphonates. While the etiopathogenesis of this condition has been investigated, the interactions and effects of bisphosphonates on oral mucosa cells remain unclear. It is hypothesized that cell culture models, such as co-culture or three-dimensional cell culture models, can provide valuable insight. Therefore, the aim of this study was to evaluate the effects of zoledronic acid (ZA) on epithelial cells and gingival fibroblasts in a co-culture model. Briefly, epithelial cells were seeded on transwell inserts and gingival fibroblasts were seeded in the lower well of 24-well plates. The latter were treated with ZA (5 μM) for 24 or 48 h. Cell viability and synthesis of the inflammatory chemokine, CCL2, were subsequently assessed. Data were subjected to statistical analysis with a 5% significance level. In the presence of ZA, the epithelial cells exhibited significant toxicity in both cell culture models and at both time points. However, greater cytotoxicity was observed in the co-culture model. Greater viability for the gingival fibroblasts was also associated with the co-culture model, and ZA-mediated toxicity was observed for the 48 h time point. ZA promoted a significant increase in CCL2 synthesis in both sets of cells, with greater CCL2 synthesis detected in the gingival fibroblasts. However, this effect was diminished in the co-culture model. Taken together, these results confirm the specific response patterns of the cells seeded in the co-culture model and also demonstrate the protective mechanism that is mediated by epithelial/mesenchymal cell interactions upon exposure to ZA.
Descritores: Técnicas de Cultura de Células/métodos
Difosfonatos/farmacologia
Células Epiteliais/efeitos dos fármacos
Conservadores da Densidade Óssea/farmacologia
Fibroblastos/efeitos dos fármacos
Imidazóis/farmacologia
-Fatores de Tempo
Ensaio de Imunoadsorção Enzimática
Sobrevivência Celular/efeitos dos fármacos
Células Cultivadas
Reprodutibilidade dos Testes
Análise de Variância
Estatísticas não Paramétricas
Técnicas de Cocultura
Proliferação de Células/efeitos dos fármacos
Ácido Zoledrônico
Gengiva/citologia
Limites: Humanos
Responsável: BR1.1 - BIREME


  2 / 203 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-952129
Autor: OH, Ji-Su; KIM, Su-Gwan.
Título: Collagen sponge and rhBMP-2 improve socket healing in rats treated with zoledronic acid
Fonte: Braz. oral res. (Online);31:e99, 2017. tab, graf.
Idioma: en.
Resumo: Abstract The aim of the present study was to evaluate the possible use of a commercial absorbed collagen sponge and bone morphogenetic protein (BMP) for the prevention of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in rats. Twenty rats received intraperitoneal injections of 0.1-mg/kg of zoledronic acid three times a week for eight weeks before the extraction of both maxillary first molars after eight weeks. A collagen sponge (experimental group 1) and a collagen sponge with recombinant human BMP-2 (experimental group 2) were applied to the right extraction sockets of ten rats each. The 20 left extraction sockets (control groups 1 and 2) were left unprotected. After eight weeks, all rats were euthanized. Macroscopic analysis, micro-computed tomography (CT) analysis, and histological analysis were performed. There was a significant difference in the bone density between the control and experimental groups on micro-CT analysis. Impaired healing of the extraction sockets, indicating BRONJ, was observed in 80% of control group 1, 90% of control group 2, 30% of experimental group 1, and 20% of experimental group 2. The collagen sponge with/without BMP used for protecting the extraction socket had the potential for a positive effect in reducing the incidence of bisphosphonate-related osteonecrosis of the jaw in rats.
Descritores: Cicatrização/efeitos dos fármacos
Tampões de Gaze Cirúrgicos
Fator de Crescimento Transformador beta/administração & dosagem
Colágeno/administração & dosagem
Alvéolo Dental/efeitos dos fármacos
Difosfonatos/farmacologia
Proteína Morfogenética Óssea 2/administração & dosagem
Osteonecrose da Arcada Osseodentária Associada a Difosfonatos/prevenção & controle
Imidazóis/farmacologia
-Proteínas Recombinantes/administração & dosagem
Ratos Sprague-Dawley
Microtomografia por Raio-X
Ácido Zoledrônico
Limites: Animais
Feminino
Ratos
Responsável: BR1.1 - BIREME


  3 / 203 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1159933
Autor: Albores, J M; Martinez Meyer, C. A; Rodriguez Fariña, R; Casares, M. S; Galan, H.
Título: Hetacilina, penicilina seminintética de amplio espectro, en el tratamiento por vía bucal de infecciones respiratorias del niño. Esquemas posológicos coda 6 y cada 12 horas / [Hetacillin, a semisynthetic broad spectrum penicillin, in oral treatment of respiratory infections in children. Posologic schedules each 6 and 12 hours]
Fonte: Arch. argent. pediatr;69(5):200-203, 1971 Jul. ilus, tab.
Idioma: es.
Descritores: Penicilinas/administração & dosagem
Infecções Respiratórias/tratamento farmacológico
-Administração Oral
Imidazóis/administração & dosagem
Limites: Humanos
Masculino
Feminino
Lactente
Pré-Escolar
Criança
Responsável: AR94.1 - Centro de Información Pediatrica


  4 / 203 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-764546
Autor: Fernández-González, Felipe José; Cañigral, Aránzazu; Balbontín-Ayala, Felipe; Gonzalo-Orden, José Manuel; Carlos, Felix de; Cobo, Teresa; Fernández-Vázquez, Jose Pedro; Sánchez-Lasheras, Fernando; Vega, José Antonio.
Título: Experimental evidence of pharmacological management of anchorage in Orthodontics: A systematic review
Fonte: Dental press j. orthod. (Impr.);20(5):58-65tab, graf.
Idioma: en.
Resumo: Introduction: Orthodontic anchorage is one of the most challenging aspects of Orthodontics. Preventing undesired movement of teeth could result in safer and less complicated orthodontic treatment. Recently, several reviews have been published about the effects of different molecules on bone physiology and the clinical side effects in Orthodontics. However, the effects of local application of these substances on the rate of orthodontic tooth movement have not been assessed.Objectives: The aim of this research was to analyze the scientific evidence published in the literature about the effects of different molecules on orthodontic anchorage.Methods: The literature was systematically reviewed using PubMed/Medline, Scopus and Cochrane databases from 2000 up to July 31st, 2014. Articles were independently selected by two different researchers based on previously established inclusion and exclusion criteria, with a concordance Kappa index of 0.86. The methodological quality of the reviewed papers was performed.Results: Search strategy identified 270 articles. Twenty-five of them were selected after application of inclusion/exclusion criteria, and only 11 qualified for final analysis. Molecules involved in orthodontic anchorage were divided into three main groups: osteoprotegerin (OPG), bisphosphonates (BPs) and other molecules (OMs).Conclusions: Different drugs are able to alter the bone remodeling cycle, influencing osteoclast function and, therefore, tooth movement. Thus, they could be used in order to provide maximal anchorage while preventing undesired movements. OPG was found the most effective molecule in blocking the action of osteoclasts, thereby reducing undesired movements.

Introdução: a ancoragem ortodôntica é um dos aspectos mais desafiadores da Ortodontia. A prevenção de movimentos dentários indesejados poderia resultar em um tratamento ortodôntico mais seguro e menos complexo. Recentemente, foram publicadas várias revisões de literatura sobre os efeitos de diferentes substâncias na fisiologia do tecido ósseo e os efeitos colaterais clínicos na Ortodontia. Porém, os efeitos da aplicação local dessas substâncias no grau de movimentação dentária ortodôntica não foram avaliados.Objetivos: o objetivo da presente pesquisa foi analisar a evidência científica publicada na literatura sobre os efeitos de diferentes substâncias na ancoragem ortodôntica.Métodos: a literatura foi sistematicamente revisada utilizando-se as bases de dados PubMed/Medline, Scopus e Cochrane, de 2000 a 31 de julho de 2014. Os artigos foram selecionados, de maneira independente, por dois pesquisadores diferentes, tendo como base critérios de inclusão e exclusão previamente estabelecidos, com um índice Kappa de concordância de 0,86. A qualidade metodológica dos artigos revisados foi analisada.Resultados: a estratégia de pesquisa identificou 270 artigos; 25 artigos foram selecionados após a aplicação dos critérios de inclusão e exclusão, mas apenas 11 foram qualificados para a análise final. As substâncias envolvidas na ancoragem ortodôntica foram divididas em três grupos principais: osteoprotegerina (OPG), bisfosfonatos (BFs) e outras substâncias (OSs).Conclusões: diferentes substâncias são capazes de alterar o ciclo de remodelação óssea, influenciando na função dos osteoclastos e, portanto, na movimentação dentária. Sendo assim, essas substâncias podem ser utilizadas para promover o máximo de ancoragem e prevenir movimentos indesejados. A OPG foi a substância mais eficaz no bloqueio da ação dos osteoclastos, reduzindo os movimentos indesejados.
Descritores: Difosfonatos/uso terapêutico
Difosfonatos/farmacologia
Anti-Inflamatórios/uso terapêutico
Anti-Inflamatórios/farmacologia
Antioxidantes/uso terapêutico
Antioxidantes/farmacologia
-Acetilcisteína/uso terapêutico
Acetilcisteína/farmacologia
Diclofenaco/uso terapêutico
Diclofenaco/farmacologia
Remodelação Óssea/efeitos dos fármacos
Ácido Clodrônico/uso terapêutico
Ácido Clodrônico/farmacologia
Procedimentos de Ancoragem Ortodôntica/métodos
Celecoxib/uso terapêutico
Celecoxib/farmacologia
Resveratrol
Ácido Zoledrônico
Pamidronato
Imidazóis/farmacologia
Limites: Humanos
Animais
Ratos
Tipo de Publ: Revisão
Revisão Sistemática
Responsável: BR1.1 - BIREME


  5 / 203 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1122665
Autor: Manubens-Vargas, Víctor; Rodríguez-Ortubia, Manuel; Salas-Gianini, Alejandra; Carreño-Toro, Laura.
Título: Paniculitis secundaria a terapia target en paciente con melanoma, lo que el dermatólogo debe saber: reporte de un caso / Panniculitis in association with target therapy in melanoma patient, what the dermatologist should know: a case report
Fonte: Medwave;20(7):e8010, 2020.
Idioma: en; es.
Resumo: Las terapias target constituyen hoy en día una alternativa terapéutica cada vez más utilizada para el manejo de pacientes con melanoma metastásico. Sin embargo, se han descrito múltiples efectos farmacológicos adversos asociados a su uso, siendo los cutáneos los de mayor prevalencia. Se presenta el caso de un hombre de 55 años con diagnóstico de melanoma cutáneo metastásico etapa IV, BRAFV600E mutado, en tratamiento con dabrafenib/trametinib que consultó por desarrollo de lesiones nodulares eritematosas sensibles en extremidades superiores e inferiores, asociadas a sensación febril durante el curso del tratamiento. Se descartó alguna infección sobreagregada. Se realizó una biopsia de las lesiones cutáneas, con confirmación diagnóstica histopatológica de una paniculitis mixta de predominio septal, granulomatosa y con vasculitis leucocitoclástica. La paniculitis asociada a esta terapia ha sido descrita en la literatura y se ha considerado un efecto farmacológico inmunomediado adverso, relacionándose a un mejor pronóstico para el melanoma metastásico en tratamiento. Por lo tanto, así como en el caso presentado, se evita la suspensión del fármaco y se asocia terapia sintomática en caso de mayores molestias del paciente. Es de alta relevancia para el dermatólogo conocer e interpretar adecuadamente este efecto adverso farmacológico, y así indicar el manejo más adecuado para el paciente.

Target therapies are currently a therapeutic option increasingly used for the management of patients with metastatic melanoma. However, there are multiple adverse pharmacological effects associated with their use that have been described. Cutaneous adverse reactions are the most frequent. We report the case of a 55-year-old man with a diagnosis of stage IV BRAFV600E-mutated metastatic cutaneous melanoma undergoing treatment with dabrafenib/trametinib, who consulted due to the development of erythematous nodular lesions in the upper and lower limbs associated with febrile sensation during the course of treatment. Infection was ruled out and a biopsy of the skin lesions was done, which provided the histopathological confirmation of a predominantly septal, granulomatous with leukocytoclastic vasculitis, mixed panniculitis. Panniculitis associated with this therapy has been described in the literature and has been considered an immune-mediated pharmacological adverse effect. It is considered to be related to a better prognosis in the treatment of metastatic melanoma. Consequently, as shown in this case report, target therapy should not be discontinued and symptomatic medication should be given to alleviate patient discomfort. The dermatologist should know and properly interpret this adverse effect and prescribe the most appropriate management for the patient.
Descritores: Paniculite/induzido quimicamente
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Terapia de Alvo Molecular/métodos
-Oximas/administração & dosagem
Piridonas/administração & dosagem
Pirimidinonas/administração & dosagem
Neoplasias Cutâneas/tratamento farmacológico
Paniculite/diagnóstico
Paniculite/terapia
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Terapia de Alvo Molecular/efeitos adversos
Dermatologistas
Imidazóis/administração & dosagem
Melanoma/tratamento farmacológico
Limites: Humanos
Masculino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: CL1.1 - Biblioteca Central


  6 / 203 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1008000
Autor: Arellano, J; Vargas, P; Urrutia, M.
Título: Primer reporte de caso autóctono de tinea nigra en Chile / First autochthonous case report of tinea nigra in Chile
Fonte: Medwave;19(6):e7666, 2019.
Idioma: en; es.
Resumo: Resumen La tinea nigra es una infrecuente micosis superficial causada por el hongo dematiáceo Hortaea werneckii. Se presenta habitualmente en zonas costeras tropicales, siendo muy escasos los reportes en países sudamericanos con climas más templados. Habitualmente corresponde a infecciones importadas por viajeros. Se presenta el caso de una paciente adulta chilena, sin historia previa de viajes recientes, cursando con cuadro clínico y microbiológico compatible con tinea nigra palmar, tratado con itraconazol oral y sertaconazol tópico con respuesta favorable. Esta paciente corresponde al primer caso reportado en Chile de origen autóctono.

Abstract Tinea nigra is an infrequent superficial mycosis caused by the dematiaceous fungus Hortaea werneckii. It usually occurs in tropical coastal areas, with very few reports in South American countries with temperate climates, generally corresponding to infections imported by travelers. We present the case of a Chilean adult patient, with no previous history of recent trips, with clinical and microbiological background consistent with palmar tinea nigra, treated with oral itraconazole and topical sertaconazole with a favorable response. This article is the first case reported in Chile, of autochthonous origin.
Descritores: Tiofenos/administração & dosagem
Tinha/diagnóstico
Itraconazol/administração & dosagem
Imidazóis/administração & dosagem
Antifúngicos/administração & dosagem
-Tinha/tratamento farmacológico
Chile
Resultado do Tratamento
Limites: Humanos
Feminino
Adolescente
Tipo de Publ: Relatos de Casos
Responsável: CL1.1 - Biblioteca Central


  7 / 203 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1159972
Autor: Martínez Meyer, C. A; Ottonello, M; Scavuzzo, F. C; Galan, H; Cedrato, A. E; Vaccaro, J; Albores, J. M.
Título: Asociación de dicloxacilina y hetacilina en pediatría. Valoración clínica, bacteriológica y de tolerancia hemática, hepática y renal en 80 niños / [Combination of dicloxacillin and hetacillin in pediatrics. Clinical and bacteriological evaluation, and blood, hepatic and renal tolerance in 80 children]
Fonte: Arch. argent. pediatr;69(9):336-339, 1971 Nov. tab.
Idioma: es.
Descritores: Oxazóis/uso terapêutico
Penicilinas/uso terapêutico
Infecções Respiratórias/tratamento farmacológico
Rim/efeitos dos fármacos
Leucócitos/efeitos dos fármacos
Fígado/efeitos dos fármacos
-Administração Oral
Dicloxacilina/uso terapêutico
Estudos de Avaliação como Assunto
Imidazóis/efeitos adversos
Imidazóis/uso terapêutico
Limites: Humanos
Masculino
Feminino
Gravidez
Recém-Nascido
Lactente
Pré-Escolar
Criança
Responsável: AR94.1 - Centro de Información Pediatrica


  8 / 203 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-897030
Autor: Tarragô, Andréa Monteiro; Pereira, Grenda Leite; Victória, Flamir da Silva; Marie, Adriana Malheiro Alle; Victória, Marilú Barbieri.
Título: Sofosbuvir and daclatasvir combination therapy for current hepatitis C virus genotype 4 achieves SVR: a case report of HCV genotype 4 from the Amazon
Fonte: Rev. Soc. Bras. Med. Trop;50(6):861-863, Nov.-Dec. 2017. tab.
Idioma: en.
Projeto: Fundação de Amparo à Pesquisa.
Resumo: Abstract Hepatitis C is a worldwide endemic disease. However, hepatitis C virus genotype 4 (HCV GT-4) has rarely been reported in Brazil. HCV GT-4 demonstrates high sustained virological response (SVR). Here, we report the case of a 62-year-old HCV GT-4 positive woman complaining of a headache, nausea, and arthralgia. The patient was treated according to the protocol for genotype 4 (12 weeks administration of 400mg sofosbuvir and 60mg daclatasvir daily) and achieved SVR. Although this is not an Amazonas autochthonous case, the presence of genotype 4 is rarely reported in the region.
Descritores: Antivirais/administração & dosagem
Hepatite C Crônica/tratamento farmacológico
Sofosbuvir/administração & dosagem
Imidazóis/administração & dosagem
-Resultado do Tratamento
Hepacivirus/genética
Hepatite C Crônica/genética
Hepatite C Crônica/virologia
Quimioterapia Combinada
Resposta Viral Sustentada
Genótipo
Pessoa de Meia-Idade
Limites: Humanos
Feminino
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  9 / 203 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1153978
Autor: Yang, Lijuan; Liu, Yepei; Wang, Yuanyuan; Li, Junsheng; Liu, Na.
Título: Azeliragon ameliorates Alzheimer's disease via the Janus tyrosine kinase and signal transducer and activator of transcription signaling pathway
Fonte: Clinics;76:e2348, 2021. graf.
Idioma: en.
Resumo: OBJECTIVES: TTP488, an antagonist of the receptor for advanced glycation end-products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD). However, the mechanism underlying the protective action of TTP488 against AD has not yet been fully explored. METHODS: Healthy male rats were exposed to aberrant amyloid β (Aβ) 1-42. Lipopolysaccharide (LPS) and the NOD-like receptor family pyrin domain containing 1 (NLRP1) overexpression lentivirus were injected to activate the NLRP1 inflammasome and exacerbate AD. TTP488 was administered to reverse AD injury. Finally, tofacitinib and fludarabine were used to inhibit the activity of Janus tyrosine kinase (JAK) and signal transducer and activator of transcription (STAT) to prove the relationship between the JAK/STAT signaling pathway and TTP488. RESULTS: LPS and NLRP1 overexpression significantly increased the NLRP1 levels, reduced neurological function, and aggravated neuronal damage, as demonstrated by the impact latency time of, time spent by, and length of the platform covered by, the mice in the Morris water maze assay, Nissl staining, and immunofluorescence staining in rats with AD. CONCLUSIONS: TTP488 administration successfully reduced AD injury and reversed the aforementioned processes. Additionally, tofacitinib and fludarabine administration could further reverse AD injury after the TTP488 intervention. These results suggest a new potential mechanism underlying the TTP488-mediated alleviation of AD injury.
Descritores: Janus Quinases/metabolismo
Doença de Alzheimer/tratamento farmacológico
-Tirosina
Transdutores
Transdução de Sinais
Peptídeos beta-Amiloides
Janus Quinase 2
Receptor para Produtos Finais de Glicação Avançada
Imidazóis
Limites: Animais
Masculino
Camundongos
Ratos
Responsável: BR1.1 - BIREME


  10 / 203 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-838088
Autor: Köklü, Seyfettin; Köksal, Iftihar; Salih Akarca, Ulus; Balkan, Ayhan; Güner, Rahmet; Demirezen, Aylin; Sahin, Memduh; Akhan, Sila; Ozaras, Resat; Idilman, Ramazan.
Título: Daclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1b Infection: Results of Turkish Early Access Program
Fonte: Ann. hepatol;16(1):71-76, Jan.-Feb. 2017. graf.
Idioma: en.
Resumo: Abstract: Background. Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1b infection in several countries. Aim. To evaluate the efficacy and safety of daclatasvir and asunaprevir dual therapy in Turkish patients. Material and methods. Sixty-one patients with HCV genotype 1b were enrolled in the Turkish early access program. Most of the patients were in difficult-to-treat category. Patients were visited at each 4 week throughout the follow-up period. Laboratory findings and adverse events were recorded at each visit. Results. Fifty-seven of 61 enrolled patients completed 24 weeks of treatment. Two patients died as a result of underlying diseases at 12-14th weeks of treatment. Two patients stopped the treatment early as a consequence of virological breakthrough, and 2 patients had viral relapse at the post-treatment follow-up. Overall SVR12 rates were 90% (55/61) and 93.2% (55/59) according to intention-to-treat (ITT) and per protocol (PP) analysis respectively. In ITT analysis, SVR12 was achieved by 93% (13/14) in relapsers, 80% (12/15) in interferon-ineligible patients and 91% (20/22) in previous nonresponder patients. SVR12 rates were 86.5% and 91.4% in patients with cirrhosis according to ITT and PP analysis respectively. SVR12 was 95.8% in non-cirrhosis group in both analysis. Patients with previous protease inhibitor experience had an SVR12 of 87.5%. Common adverse events developed in 28.8% of patients. There were no treatment related severe adverse event or grade-4 laboratory abnormality. Conclusions. Daclatasvir and asunaprevir dual therapy is found to be effective and safe in difficult-to-treat Turkish patients with HCV genotype 1b infection.
Descritores: Antivirais/uso terapêutico
Sulfonamidas/uso terapêutico
Hepacivirus/efeitos dos fármacos
Hepatite C Crônica/tratamento farmacológico
Acesso aos Serviços de Saúde
Imidazóis/uso terapêutico
Isoquinolinas/uso terapêutico
-Antivirais/economia
Antivirais/efeitos adversos
Sulfonamidas/economia
Sulfonamidas/efeitos adversos
Fatores de Tempo
Turquia
RNA Viral/genética
Avaliação de Programas e Projetos de Saúde
Resultado do Tratamento
Custos de Medicamentos
Análise Custo-Benefício
Hepacivirus/genética
Carga Viral
Hepatite C Crônica/diagnóstico
Hepatite C Crônica/economia
Hepatite C Crônica/virologia
Quimioterapia Combinada
Genótipo
Acesso aos Serviços de Saúde/economia
Imidazóis/economia
Imidazóis/efeitos adversos
Isoquinolinas/economia
Isoquinolinas/efeitos adversos
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Idoso
Responsável: BR1.1 - BIREME



página 1 de 21 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde